Pharmaceutical News

RSS

D2 Pharma Consulting develops "REMS Challenges and Real World Solutions" White Paper

D2 Pharma Consulting LLC (D2) is a best-in-class national consulting company that works with pharmaceutical and biotech manufacturers on the implementation of REMS compliant distribution programs, in addition to other commercialization activities. D2 structures REMS distribution programs on behalf of their clients that leverage supply chain efficiencies while complying with FDA mandates.

21 Oct 2009

Drug abuse expert Dr. Drew Pinsky and the Five Moms join in fight against OTC cough medicine abuse

Dr. Drew Pinsky, a nationally renowned drug abuse expert, and the Five Moms, five exceptional women dedicated to spreading the word about the dangers of cough medicine abuse, are speaking out to educate parents and congressional staff on Capitol Hill about the issue of over-the-counter (OTC) cough medicine abuse among teens and how to prevent it through education.

21 Oct 2009

NIH grant for Lpath to advance clinical development of its antibody therapeutics

The National Cancer Institute's Small Business Innovation Research (SBIR) Program has awarded Lpath (OTCBB: LPTN), the category leader in lipidomics-based therapeutics, two Phase 1 grants totaling $0.3 million. This follows a series of other SBIR grants awarded to Lpath totaling $6.9 million, including a $3.0 million Phase 2 bridge grant from the NCI awarded this past June.

21 Oct 2009

No significant differences in pregnancy outcomes with different progesterone formulations

A retrospective analysis, conducted at a large infertility clinic between January 2003 and December 2008, demonstrated that there were no significant differences in pregnancy outcomes with three different progesterone formulations for women aged 35 to 40 undergoing in vitro fertilization-embryo transfer (IVF-ET) procedures. These data were presented at the American Society for Reproductive Medicine (ASRM) annual meeting in Atlanta.

21 Oct 2009

Research shows exon-skipping drug may prove effective for treating Duchenne muscular dystrophy

An exon skipping PPMO has demonstrated dramatic effects in the prevention and treatment of severely affected, dystrophin and utrophin-deficient mice, preventing severe deterioration of the treated animals and extending their lifespan.

21 Oct 2009

Wellstat Therapeutics and Sanofi-Aventis to develop, manufacture and commercialize PN2034

Wellstat Therapeutics Corporation and sanofi-aventis announced today a global licensing agreement to develop, manufacture and commercialize PN2034, a first-in-class oral insulin sensitizer for the treatment of Type II diabetes.

21 Oct 2009

Logical Therapeutics to present its clinical study results on LT-NS001

Logical Therapeutics, Inc. (Logical), a biopharmaceutical company focused on developing products that treat medical conditions associated with inflammation, has been selected to present the results of its clinical study comparing the gastrointestinal (GI) safety of its lead product LT-NS001, vs. naproxen at the American College of Gastroenterology's (ACG) Annual Scientific Meeting on October 27, 2009.

21 Oct 2009

CHA urges California Nurses Association to promote vaccinations to all health care workers

The California Hospital Association (CHA) is engaged with hospitals and state and local public health officials in a voluntary statewide effort to ensure that all hospital workers -- including registered nurses -- are vaccinated against the H1N1 flu virus.

21 Oct 2009

Novo Nordisk's Levemir not associated with increase in the incidence of cancer

A meta-analysis of clinical data published today in Diabetologia, the medical journal for the European Association for the Study of Diabetes (EASD), demonstrated that the Novo Nordisk long-acting insulin Levemir® (insulin detemir [rDNA origin] injection) was not associated with any increase in the incidence of cancer when compared to human insulin.

From Novo Nordisk 21 Oct 2009

Osteologix to continue clinical development of NB S101 osteoporosis drug

Osteologix, Inc., a bio-pharmaceutical company announced today that the company will continue the clinical development for its osteoporosis drug, NB S101 (strontium malonate), in the United States and the rest of the world markets. Additionally, the company wants to recognize World Osteoporosis Day’s significance and make more people aware of its research dedicated to improving the lives of people with osteoporosis.

21 Oct 2009

Simcere and OSI Pharmaceuticals to market KDR/Kit inhibitor OSI-930 in China

Simcere Pharmaceutical Group ("Simcere" or the "Company"), a leading pharmaceutical company specializing in development, manufacturing, and marketing of branded generic and proprietary pharmaceuticals in China, today announced an agreement with OSI Pharmaceuticals, Inc., to develop, manufacture, and market its KDR/Kit inhibitor OSI-930 in China.

21 Oct 2009

Inovio Biomedical highlights its advances in SynCon DNA vaccines

Inovio Biomedical Corporation, a leader in DNA vaccine design, development and delivery, announced that Dr. David B. Weiner, Chairman of Inovio’s Scientific Advisory Board, highlighted advances in electroporation-delivered SynCon™ DNA vaccines compared to other leading vaccine technologies at the AIDS Vaccine 2009 Conference being held this week in Paris, France.

21 Oct 2009

As HIV vaccine conference opens, experts appeal for sustained commitment to global fight against disease

Experts, gathered for the start of a four-day conference on HIV vaccines in Paris, called upon donors to maintain their funding support for the fight against HIV/AIDS despite the global economy, Agence France-Presse reports.

20 Oct 2009

ImPACKD calls for raising awareness about the risks of calcium overuse in CKD patients

Most Canadians living with CKD have likely never spoken with their physicians about calcium and the serious health risks associated with its overuse. This is why Improving Patient Advocacy in Chronic Kidney Disease (ImPACKD), a group of CKD patients and caregivers committed to raising awareness about the risks of calcium overuse, is starting the conversation about the importance of knowing the limits and keeping them in check.

20 Oct 2009

Merck Frosst Canada announces the use of ISENTRESS for treating HIV-1 infected adults

Merck Frosst Canada Ltd. is pleased to announce that (Pr)ISENTRESS(R) (raltegravir) is now indicated for use in treatment-naïve HIV-1 infected adults in combination with other antiretroviral agents.

20 Oct 2009

Boehringer Ingelheim continues providing non assert declarations to manufacture HIV/AIDS medicines

Boehringer Ingelheim continues to be willing to provide WHO qualified generic pharmaceutical companies non assert declarations to manufacturer and export products containing the HIV/AIDS medication nevirapine to Rwanda and other defined developing countries.

20 Oct 2009

TechnoVax receives NIH grant to further the development of its VLP-based, vaccine program

TechnoVax, Inc., a biotechnology developer of novel vaccines was awarded a three-year $2.9 million SBIR phase II grant from the National Institutes of Health to further the development of its VLP-based, vaccine program.

20 Oct 2009

Meeting to discuss latest information on anti-aging medicine and euthanasia

America's foremost authorities on aging will share the latest information on "death panels," anti-aging medicine, health care reform, and other current topics at The Gerontological Society of America's upcoming 62nd Annual Scientific Meeting. This four day event - the country's largest interdisciplinary conference in the field of aging - will take place from November 18 to 22 in Atlanta, GA. Media representatives can register free of charge.

20 Oct 2009

GlaxoSmithKline to allow Apotex continue manufacturing their drug in Rwanda

GlaxoSmithKline Inc. (GSK) As part of its broad commitment to improving access to medicines and its ongoing support for Canada's Access to Medicines Regime (CAMR), GlaxoSmithKline confirms it will not object - through CAMR - to allow Canadian company (Apotex) to continue manufacturing their drug for the treatment of HIV/AIDS in Rwanda.

20 Oct 2009

USP offers redesigned pharmaceutical standards format to improve key documentation process

To improve key documentation relied upon by the pharmaceutical industry and others, the U.S. Pharmacopeial (USP) Convention announces the release of the redesigned United States Pharmacopeia-National Formulary (USP-NF).

20 Oct 2009

Pharmaceutical News

D2 Pharma Consulting develops "REMS Challenges and Real World Solutions" White Paper

Drug abuse expert Dr. Drew Pinsky and the Five Moms join in fight against OTC cough medicine abuse

NIH grant for Lpath to advance clinical development of its antibody therapeutics

No significant differences in pregnancy outcomes with different progesterone formulations

Research shows exon-skipping drug may prove effective for treating Duchenne muscular dystrophy

Wellstat Therapeutics and Sanofi-Aventis to develop, manufacture and commercialize PN2034

Logical Therapeutics to present its clinical study results on LT-NS001

CHA urges California Nurses Association to promote vaccinations to all health care workers

Novo Nordisk's Levemir not associated with increase in the incidence of cancer

Osteologix to continue clinical development of NB S101 osteoporosis drug

Simcere and OSI Pharmaceuticals to market KDR/Kit inhibitor OSI-930 in China

Inovio Biomedical highlights its advances in SynCon DNA vaccines

As HIV vaccine conference opens, experts appeal for sustained commitment to global fight against disease

ImPACKD calls for raising awareness about the risks of calcium overuse in CKD patients

Merck Frosst Canada announces the use of ISENTRESS for treating HIV-1 infected adults

Boehringer Ingelheim continues providing non assert declarations to manufacture HIV/AIDS medicines

TechnoVax receives NIH grant to further the development of its VLP-based, vaccine program

Meeting to discuss latest information on anti-aging medicine and euthanasia

GlaxoSmithKline to allow Apotex continue manufacturing their drug in Rwanda

USP offers redesigned pharmaceutical standards format to improve key documentation process

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Latest News